C
Cara Lunn Shirai
Researcher at Washington University in St. Louis
Publications - 21
Citations - 453
Cara Lunn Shirai is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Haematopoiesis & Gene. The author has an hindex of 6, co-authored 15 publications receiving 343 citations.
Papers
More filters
Journal ArticleDOI
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
Cara Lunn Shirai,James N Ley,Brian S. White,Sang-hyun Kim,Justin Tibbitts,Jin Shao,Matthew Ndonwi,Brian A. Wadugu,Eric J. Duncavage,Theresa Okeyo-Owuor,Tuoen Liu,Malachi Griffith,Sean McGrath,Vincent Magrini,Robert S. Fulton,Catrina Fronick,Michelle O'Laughlin,Timothy A. Graubert,Matthew J. Walter +18 more
TL;DR: In this paper, the authors examined in vivo hematopoietic consequences of the most common U2AF1 mutation using a doxycycline-inducible transgenic mouse model.
Journal ArticleDOI
Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
Cara Lunn Shirai,Brian S. White,Manorama Tripathi,Roberto Tapia,James N Ley,Matthew Ndonwi,Sang-hyun Kim,Jin Shao,Alexa Carver,Borja Saez,Robert S. Fulton,Catrina Fronick,Michelle O'Laughlin,Chandraiah Lagisetti,Thomas R. Webb,Timothy A. Graubert,Matthew J. Walter +16 more
TL;DR: It is found that haematopoietic cells expressing mutant U2AF1(S34F), including primary patient cells, have an increased sensitivity to in vitro sudemycin treatment relative to controls, suggesting a potential for treating haem atological cancers harbouring U2 AF1 mutations with pre-mRNA splicing modulators like sudemies.
Journal ArticleDOI
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
TL;DR: Ruxolitinib was an effective salvage therapy for relapsed/refractory secondary hemophagocytic lymphohistiocytosis and the need for intensive chemotherapy or allogeneic transplant in secondary HLH was eliminated.
Journal ArticleDOI
Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
Tuoen Liu,Kilannin Krysiak,Cara Lunn Shirai,Sang-hyun Kim,Jin Shao,Matthew Ndonwi,Matthew J. Walter +6 more
TL;DR: Findings indicate that reduced levels of HSPA9 may contribute to TP53 activation and increased apoptosis observed in del(5q)-associated MDS.
Journal ArticleDOI
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.
TL;DR: This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.